@GSpier@BeckyQuick Consider Dr. Keyoars Ashkan at Kings College Hospital, London. He was the European chief investigator for an Autologous Tumor Lysate which has completed Phase III trial and is pending approval in the UK by the MHRA.
@GSpier@BeckyQuick Consider Dr. Keyoars Ashkan at Kings College Hospital, London. He was the European chief investigator for an Autologous Tumor Lysate which has completed Phase III trial and is pending approval in the UK by the MHRA.
@GSpier@BeckyQuick If you have not had your tumor material cryopreserved, do that for the next resection.
Musella Foundation has information on DCVax-L: https://t.co/CUAqpyJYxS
@DCVaxDefender@dennisedugan Money isn’t exactly growing on trees for us at the moment, so there isn’t a remote chance shareholder value will be returned in the form of a buyback or dividend any time soon.
@neilmck37597308@Investors_Hub “ We are hopeful that this will unlock further innovative treatments and ensure more promising drugs clear the threshold for approval, opening up new opportunities and better outcomes for brain tumour patients. ”
“…a welcome step forward…”
The stage is set.